Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA ASTRAZENECA PHARMA AJANTA PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 27.6 145.2 19.0% View Chart
P/BV x 6.8 40.8 16.7% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 AJANTA PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
ASTRAZENECA PHARMA
Mar-18
AJANTA PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,4221,278 111.3%   
Low Rs898883 101.7%   
Sales per share (Unadj.) Rs233.5228.4 102.2%  
Earnings per share (Unadj.) Rs44.010.4 424.2%  
Cash flow per share (Unadj.) Rs52.216.3 320.7%  
Dividends per share (Unadj.) Rs9.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs255.198.8 258.3%  
Shares outstanding (eoy) m88.0225.00 352.1%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.04.7 105.0%   
Avg P/E ratio x26.4104.2 25.3%  
P/CF ratio (eoy) x22.266.4 33.5%  
Price / Book Value ratio x4.510.9 41.6%  
Dividend payout %20.50-   
Avg Mkt Cap Rs m102,08127,008 378.0%   
No. of employees `0006.81.4 501.5%   
Total wages/salary Rs m4,3071,535 280.5%   
Avg. sales/employee Rs Th3,022.64,210.9 71.8%   
Avg. wages/employee Rs Th633.41,132.2 55.9%   
Avg. net profit/employee Rs Th569.1191.1 297.8%   
INCOME DATA
Net Sales Rs m20,5545,710 360.0%  
Other income Rs m211123 172.1%   
Total revenues Rs m20,7655,833 356.0%   
Gross profit Rs m5,664463 1,223.7%  
Depreciation Rs m721147 489.0%   
Interest Rs m120-   
Profit before tax Rs m5,143438 1,174.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,273179 711.6%   
Profit after tax Rs m3,870259 1,493.5%  
Gross profit margin %27.68.1 339.9%  
Effective tax rate %24.840.8 60.6%   
Net profit margin %18.84.5 414.9%  
BALANCE SHEET DATA
Current assets Rs m11,8123,209 368.1%   
Current liabilities Rs m3,7762,070 182.5%   
Net working cap to sales %39.120.0 195.9%  
Current ratio x3.11.6 201.7%  
Inventory Days Days7772 107.0%  
Debtors Days Days8235 233.7%  
Net fixed assets Rs m14,398790 1,821.9%   
Share capital Rs m17550 350.8%   
"Free" reserves Rs m22,2772,419 920.8%   
Net worth Rs m22,4522,469 909.2%   
Long term debt Rs m70-   
Total assets Rs m26,9624,605 585.4%  
Interest coverage x444.3NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.81.2 61.5%   
Return on assets %14.45.6 255.9%  
Return on equity %17.210.5 164.3%  
Return on capital %23.017.7 129.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,682300 3,565.9%   
Fx outflow Rs m2,1022,015 104.3%   
Net fx Rs m8,580-1,715 -500.2%   
CASH FLOW
From Operations Rs m3,74888 4,263.7%  
From Investments Rs m-2,228-94 2,380.3%  
From Financial Activity Rs m-1,475NA-  
Net Cashflow Rs m45-6 -793.0%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 1.6 0.3 516.7%  
FIIs % 7.6 15.7 48.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 9.1 186.8%  
Shareholders   20,968 12,856 163.1%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ELDER PHARMA  FDC  SUN PHARMA  WYETH  NOVARTIS  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 470 Points Lower; Tata Motors & Tata Steel Fall 6%(Closing)

Indian share markets witnessed huge selling pressure today, in line with global equities and fell on to bearish territory.

Related Views on News

ASTRAZENECA PHARMA Share Price Down by 5%; BSE HEALTHCARE Index Down 2.5% (Market Updates)

Jan 18, 2021 | Updated on Jan 18, 2021

ASTRAZENECA PHARMA share price is trading down by 5% and its current market price is Rs 4,200. The BSE HEALTHCARE is down by 2.5%. The top gainers in the BSE HEALTHCARE Index are GSK PHARMA (up 1.2%) and IPCA LABS (up 1.0%). The top losers are ASTRAZENECA PHARMA (down 5.3%) and WOCKHARDT (down 5.2%).

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 45.3% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 45.3% YoY). Sales on the other hand came in at Rs 7 bn (up 32.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 18, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS